Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fovista and Anti-VEGF for Subfoveal Fibrosis in nAMD
NCT02591914Phase 1Completed
- Sponsor
- Retinal Consultants of Arizona
- Start
- Feb 2014
- Primary completion
- May 2016
- Modality
- Polymer-based Nanoparticles, RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pegpleranib in neovascular age-related macular degeneration (NVAMD), sponsored by Retinal Consultants of Arizona. Primary endpoint: Safety and Tolerability at Month 24. Started Feb 2014; status: completed.
02
Drugs
pegpleranib
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02591914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02591914.